Payment overview · 2025
General Payments
$1,076.16
18 reported records · 7 companies
Healthcare provider profile · identity verified
Mallory Elyse Mowdy, NP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · BROOKHAVEN, MS · NPI 1427458553
Verified facts
What the public records show
CMS Open Payments records show Mallory Elyse Mowdy, NP-C received $1,076.16 in general payments during 2025 across 18 reported records.
Biogen, Inc. accounted for 65.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Linzess by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SKYCLARYS as an associated drug or biological on 3512 records involving 2165 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Skyclarys by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Biogen, Inc. | Unresolved — no canonical attribution shown | $704.00 | 65.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $162.41 | 15.1% | 10 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $135.67 | 12.6% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $23.15 | 2.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.26 | 1.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.74 | 1.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.93 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $704.00 | 1 |
| Food and Beverage | $372.16 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $142.05 | 9 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $135.67 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $64.28 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $23.15 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $16.74 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
99 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | SKYCLARYS open payments reported associated product |
CMS Open Payments — General Payments 3512 supporting records · 2165 recipient NPIs · example record 1208299709 |
Skyclarys · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 260 | 29 |
| Levothyroxine Sodium | Levothyroxine Sodium | 228 | 25 |
| Simvastatin | Simvastatin | 210 | 21 |
| Olanzapine | Olanzapine | 182 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 179 | 15 |
| Amlodipine Besylate | Amlodipine Besylate | 177 | 19 |
| Trazodone Hcl | Trazodone Hcl | 144 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 133 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 132 | 12 |
| Benztropine Mesylate | Benztropine Mesylate | 128 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 117 | suppressed |
| Lisinopril | Lisinopril | 110 | 12 |
| Divalproex Sodium Er | Divalproex Sodium | 105 | suppressed |
| Linzess | Linaclotide | 99 | suppressed |
| Aripiprazole | Aripiprazole | 98 | suppressed |
| Metformin Hcl | Metformin Hcl | 91 | suppressed |
| Valsartan | Valsartan | 86 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 84 | suppressed |
| Levetiracetam | Levetiracetam | 81 | suppressed |
| Risperidone | Risperidone | 80 | suppressed |
| Vascepa | Icosapent Ethyl | 78 | suppressed |
| Losartan Potassium | Losartan Potassium | 77 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 75 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 62 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 57 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 57 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 51 | suppressed |
| Gabapentin | Gabapentin | 51 | 14 |
| Potassium Chloride | Potassium Chloride | 51 | suppressed |
| Furosemide | Furosemide | 49 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 49 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 45 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 44 | suppressed |
| Meloxicam | Meloxicam | 40 | suppressed |
| Lactulose | Lactulose | 39 | suppressed |
| Clonazepam | Clonazepam | 38 | suppressed |
| Famotidine | Famotidine | 38 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Tradjenta | Linagliptin | 35 | suppressed |
| Clozapine | Clozapine | 33 | suppressed |
| Lacosamide | Lacosamide | 33 | suppressed |
| Carbamazepine | Carbamazepine | 31 | suppressed |
| Naproxen | Naproxen | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Haloperidol | Haloperidol | 29 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 29 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 27 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Allopurinol | Allopurinol | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Scopolamine | Scopolamine | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 19 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Klor-Con 10 | Potassium Chloride | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Carvedilol | Carvedilol | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Skyclarys | Omaveloxolone | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 11 | suppressed |
| Briviact | Brivaracetam | 11 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 11 | suppressed |
| Paliperidone Er | Paliperidone | 11 | suppressed |
| Phenytoin | Phenytoin | 11 | suppressed |
| Rufinamide | Rufinamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,076.16 · 18 records | Biogen, Inc. | AUSTEDO XR, Auvelity, CAPLYTA, ELIQUIS, Korlym, NURTEC ODT, QULIPTA, UBRELVY | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error